Two Cities, One Mission｜ASPCR Shanghai × CUHK Hong Kong

Advancing Vitiligo and Pigmentary Research Across Asia

This past weekend, our research team actively participated in two major international dermatology congresses, presenting the latest findings in vitiligo and pigmentary disorders.

▍First Stop: Shanghai

At the 12th Annual Meeting of the Asian Society for Pigment Cell Research (ASPCR 2025), our physician was invited to serve as session chair of the Clinical Research in Pigmentary Disorders track and delivered a keynote titled:
"Innovations in Vitiligo: From AI Imaging, Biomarkers to Targeted Therapy",
which explored novel approaches in vitiligo diagnosis and treatment—from AI-based skin imaging and biomarker profiling to the development of targeted immunotherapies.

Our team also presented clinical trial data on cysteamine for melasma and post-laser hyperpigmentation, showcasing our broad expertise in pigmentary research.

A highlight of the event was our junior physician, Dr. Hsin-Yu, who received the Young Investigator Award for her outstanding research on vitiligo relapse risk factors—a proud moment for our team and for Taiwan on the international stage.

▍Second Stop: Hong Kong

Following Shanghai, our team was invited by The Chinese University of Hong Kong to speak at the "Advances in Medicine: Dermatology Plenary", presenting:
"From Zero to One – Latest Advances in Vitiligo"
The talk covered IFN-γ–mediated melanocyte destruction pathways and our targeted anti–IFN-γ strategies, along with real-world insights into the first FDA-approved vitiligo therapy—ruxolitinib 1.5% cream.

✨ Every step forward brings new hope.
From "no cure" to "evidence-based care," we remain committed to advancing vitiligo treatment through collaboration and innovation.

📖 Further Reading:
From Zero to One: Recent Advances in the Treatment of Vitiligo